Clot-Buster Drug Gets DCGI Clearance For Human Trial

by VR Sreeraman on  August 18, 2012 at 7:00 PM Clinical Trials News
RSS Email Print This Page Comment
The Drug Controller General of India (DCGI) has cleared a bio-therapeutic clot-buster drug for phase-one human clinical trials, a statement said Friday.
 Clot-Buster Drug Gets DCGI Clearance For Human Trial
Clot-Buster Drug Gets DCGI Clearance For Human Trial
Advertisement

The drug, earlier licensed from a US-based firm, has been designed by Chandigarh-based Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (CSIR-IMTECH).

Advertisement
"Clot-specific streptokinase (CSSK), a pioneering bio-therapeutic clot buster drug from the CSIR-IMTECH has been cleared Thursday by the office of the DCGI for Phase-One Human Clinical trials," the statement from CSIR said.

The drug is helpful in saving lives of patients suffering heart attacks; it can also reduce the risk of internal bleeding, associated with the use of clot busters.

The drug has recently been successfully tried in test animals including monkeys. Its design and process development and scale-up was achieved by a team led by CSIR-IMTECH Director Girish Sahni.

Source: IANS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive